Correction to: Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly

Sabrina Chiloire¹ · Gherardo Mazziotti² · Antonella Giampietro¹ · Antonio Bianchi¹ · Stefano Frara³ · Marilda Mormando¹ · Alfredo Pontecorvi¹ · Andrea Giustina³ · Laura De Marinis¹

Published online: 23 February 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Correction to: Pituitary
<https://doi.org/10.1007/s11102-018-0873-7>

The original version of the article contained an error in the results section of the Abstract. The vertebral fractures (VFs) odds ratio is incorrectly published as 61.0 and the correct value is 6.10.

The text should read as, In the multivariate logistic regression analysis, incident VFs were independently predicted by pre-existing VFs (odds ratio 6.10; $p=0.009$), duration of active acromegaly (odds ratio 1.01; $p=0.05$) and mean serum IGF-I during the follow-up (odds ratio 5.26; $p=0.03$), regardless of the therapeutic regimen (odds ratio 1.05; $p=0.94$).

The original article can be found online at <https://doi.org/10.1007/s11102-018-0873-7>.

✉ Laura De Marinis
laurademarinis@yahoo.it

¹ Pituitary Unit, Catholic University of the Sacred Heart, Rome, Italy

² Endocrine Unit, ASST Carlo Poma, Mantua, Italy

³ Vita-Salute San Raffaele University, Milan, Italy